InterLeukin6 IL6 Inhibitor Market 2024

The interleukin6 (IL-6) inhibitor market size has grown rapidly in recent years. It will grow from $29.47 billion in 2023 to $32.57 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historic period can be attributed to several factors, including the rise in clinical trials and research, heightened awareness of IL-6 inhibitors, increased patient advocacy and demand, expanded public awareness and education, and the emergence of biosimilars.

The interleukin6 (IL-6) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $48.55 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth during the forecast period is expected to be driven by factors such as improvements in healthcare system infrastructure, regulatory and policy changes, increased funding and investment, developments in the pharmaceutical pipeline, and endorsements from the medical community. Key trends anticipated in this period include advancements in molecular engineering, the development of novel biologics, exploration of new therapeutic areas, integration with genomic and proteomic data, and enhanced drug delivery systems.

The rising prevalence of neurological disorders is projected to drive the growth of the interleukin-6 (IL-6) inhibitor market in the coming years. Neurological disorders encompass a broad spectrum of conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves. The increasing incidence of these disorders is attributed to factors such as an aging population, improved diagnostic techniques, heightened awareness, and lifestyle elements such as stress, sedentary behavior, and poor diet. IL-6 inhibitors play a critical role in managing neurological disorders by mitigating inflammation and reducing immune system overactivity in the brain, which can alleviate symptoms and slow disease progression in conditions such as multiple sclerosis and Alzheimer's disease. For example, a report from the National Library of Medicine in March 2023 estimated that approximately 6.7 million Americans aged 65 and older would be living with Alzheimer's dementia in 2023, a number projected to rise to 13.8 million by 2060. Consequently, the growing prevalence of neurological disorders is significantly driving the interleukin-6 inhibitor market.

Key players in the interleukin-6 (IL-6) inhibitor market are focused on developing advanced solutions, such as the first approved tocilizumab biosimilar, to broaden treatment options and enhance patient outcomes. The first approved tocilizumab biosimilar is a highly similar version of the original Actemra, which is an IL-6 receptor inhibitor used to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. For instance, in November 2023, Fresenius Kabi, a Germany-based healthcare company, launched Tyenne, a treatment for various inflammatory and immune-mediated conditions. This medication offers flexible administration options, including subcutaneous (via prefilled syringes and autoinjectors) and intravenous (via vials) formulations, allowing healthcare providers to tailor treatment to individual patient needs. Tyenne presents an accessible, affordable, high-quality, and safe alternative for European patients currently receiving tocilizumab.

In March 2022, Recordati Industria Chimica e Farmaceutica S.p.A., an Italy-based pharmaceutical company, acquired EUSA Pharma (UK) Ltd. for an undisclosed amount. This acquisition aims to broaden Recordati's portfolio in the rare disease segment, enhance its therapeutic focus on rare and niche oncology diseases, and improve its capacity to deliver innovative treatments that address significant unmet medical needs. EUSA Pharma (UK) Ltd. is a UK-based pharmaceutical company specializing in rare and oncology products, including SYLVANT (siltuximab).

Major companies operating in the interleukin6 (IL-6) inhibitor market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Sanofi S.A., Galapagos N.V., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogene Inc., Chugai Pharmaceutical Co Ltd., Celltrion Inc., Dynavax Technologies Corporation, Argenx SE, Aclaris Therapeutics Inc., Genentech Inc., Evelo Biosciences Inc., BPS Bioscience Inc., Tiziana Life Sciences PLC.

Asia-Pacific was the largest region in the interleukin6 (IL-6) inhibitor market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the interleukin6 il6 inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the interleukin6 il6 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Interleukin-6 (IL-6) inhibitors are medications that block the activity of IL-6, a cytokine involved in inflammation and immune responses. These inhibitors are utilized to treat conditions such as rheumatoid arthritis, certain cancers, and other inflammatory diseases. By targeting IL-6, they help reduce inflammation and modulate the immune system.

The primary product types of IL-6 inhibitors include tocilizumab, siltuximab, and sylvan. Tocilizumab is a monoclonal antibody that blocks the IL-6 receptor and is used to treat inflammatory conditions such as rheumatoid arthritis and cytokine release syndrome. It can be administered through various routes, including intravenous (IV), subcutaneous (SC), and others. The indications for IL-6 inhibitors encompass rheumatoid arthritis, oncology, systemic juvenile idiopathic arthritis, giant cell arteritis, and COVID-19-related cytokine storm, among others. Distribution channels include retail pharmacies, hospital pharmacies, specialty pharmacies, online pharmacies, and more.

The interleukin6 (IL-6) inhibitor market research report is one of a series of new reports that provides interleukin6 (IL-6) inhibitor market statistics, including the interleukin6 (IL-6) inhibitor industry's global market size, regional shares, competitors with an interleukin6 (IL-6) inhibitor market share, detailed interleukin6 (IL-6) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin6 (IL-6) inhibitor industry. This interleukin6 (IL-6) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The interleukin6 (IL-6) inhibitor market consists of sales of clazakizumab, sirukumab, olokizumab, brezulimab, and mavrilimumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.